Bio-Nexus

Mobile Management and Communication Tools

Health Tech & Life Sciences
Non Active, Dec 2019 ceased to operate
Follow

Company Overview

Snapshot

Founded in October 2010 by Ztiki Fuchs, Bio-Nexus operates with 1–10 employees. The company has raised $3 million across one funding round from Springtide Ventures. In August 2017, Bio-Nexus announced its acquisition of Cleerio.

Business overview

Bio-Nexus develops software technology that digitizes workflow processes to create interactive protocols and digital records. The Bio-Nexus Mobile Platform serves as a mobile tool for managers and maintenance teams, addressing challenges in high-cost, high-risk workflows. Additionally, the company offers a mobile medical platform for military and civilian sectors, providing an end-to-end, cross-platform solution for interactive digital medical records with dynamic interfaces and bi-directional information exchange. Bio-Nexus operates within the Health Tech & Life Sciences sector, focusing on Digital Healthcare and Clinical Workflow solutions.

Strategic signal

In August 2017, Bio-Nexus announced the acquisition of Cleerio. This strategic move indicates the company's intent to expand its technological capabilities and market reach, suggesting a focus on integrating new solutions to enhance its mobile management and communication tools.

Log in to access full profile

Company Intelligence Q&A

What is Bio-Nexus's primary business?
Bio-Nexus specializes in developing software technology that digitizes workflow processes to create interactive protocols and digital records, primarily through its mobile platform for management, maintenance, and medical applications.
When was Bio-Nexus founded?
Bio-Nexus was founded in October 2010.
Who are the founders of Bio-Nexus?
Ztiki Fuchs is a co-founder of Bio-Nexus.
What was a significant corporate development for Bio-Nexus in 2017?
In August 2017, Bio-Nexus announced its acquisition of Cleerio.
What is the status of Bio-Nexus?
Bio-Nexus is non-active and ceased to operate in December 2019.
Log in to access full profile